Skip to Content

Sarepta Therapeutics Inc SRPT

Morningstar Rating
$122.84 −2.16 (1.73%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SRPT is trading at a 747% premium.
Price
$122.22
Fair Value
$972.95
Uncertainty
Very High
1-Star Price
$387.84
5-Star Price
$937.35
Economic Moat
Lmhfd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRPT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$125.00
Day Range
$120.34125.89
52-Week Range
$55.25146.68
Bid/Ask
$120.50 / $123.00
Market Cap
$11.61 Bil
Volume/Avg
1.0 Mil / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
114.82
Price/Sales
8.33
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
1,314

Comparables

Valuation

Metric
SRPT
RARE
FOLD
Price/Earnings (Normalized)
114.82
Price/Book Value
12.0823.1322.99
Price/Sales
8.336.807.14
Price/Cash Flow
78.97
Price/Earnings
SRPT
RARE
FOLD

Financial Strength

Metric
SRPT
RARE
FOLD
Quick Ratio
2.972.092.22
Current Ratio
4.052.433.03
Interest Coverage
−1.00−8.73−1.89
Quick Ratio
SRPT
RARE
FOLD

Profitability

Metric
SRPT
RARE
FOLD
Return on Assets (Normalized)
6.50%−35.51%−6.98%
Return on Equity (Normalized)
25.41%−299.94%−40.42%
Return on Invested Capital (Normalized)
7.51%−224.67%−2.87%
Return on Assets
SRPT
RARE
FOLD
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
CkjrdfcGljggm$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
SvnkxpnqBckdk$114.2 Bil
Moderna Inc
MRNA
MmwlvnsrWhfh$53.7 Bil
argenx SE ADR
ARGX
QzryvctfWsz$23.0 Bil
BioNTech SE ADR
BNTX
NqlxxgpnKsff$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
NvmxpvbgHnjcf$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
BtnldjvtYwdytg$15.9 Bil
United Therapeutics Corp
UTHR
RbsrdrsNsf$12.8 Bil
Incyte Corp
INCY
GmgmwlfXmthww$12.2 Bil
Royalty Pharma PLC Class A
RPRX
KgwbzzktpTgpcyw$12.2 Bil

Sponsor Center